Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will host a webcast and conference call on August 4, 2020, at 11:00 a.m. EDT to discuss its second quarter financial results and business updates for the period ending June 30, 2020. Interested participants can dial in at (866) 503-5561 (U.S. toll-free) or (253) 336-2965, using conference ID 5884198. A replay will be available post-call until August 7, 2020. The live webcast can be accessed via the Company's Investor page.

SAN DIEGO, July 23, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the second quarter ended June 30, 2020.

Date	Tuesday, August 4, 2020
Time	11:00 a.m. EDT (8:00 a.m. PDT)
Dial-in numbers	(866) 503-5561 (U.S. toll-free) or (253) 336-2965
Conference ID	5884198
Webcast (live and archived)	www.evofem.com under "Investors" or click here

The live webcast and related slide presentation can be accessed on the Company's Investor page at https://evofem.investorroom.com/events. Please connect to the Company's website at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 10 minutes prior to the start of the call.

A telephone replay will be available approximately two hours after the call through Friday, August 7, 2020 at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 5884198. The webcast will be archived at https://evofem.investorroom.com/events. 

About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only vaginal pH regulator approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women.

Contact
Investor Relations
Amy Raskopf
Evofem Biosciences
araskopf@evofem.com 
O: (858) 550-1900 x167
M: (917) 673-5775

Media
Cara Miller
Evofem Biosciences
cmiller@evofem.com 
O: (858) 550-1900 x272

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2020-results-and-provide-corporate-update-on-tuesday-august-4-2020-301098441.html

SOURCE Evofem Biosciences, Inc.

FAQ

When will Evofem Biosciences report its second quarter 2020 results?

Evofem Biosciences will report its second quarter 2020 results on August 4, 2020.

What time will the Evofem Biosciences conference call take place?

The conference call will occur at 11:00 a.m. EDT on August 4, 2020.

How can I access the Evofem Biosciences conference call?

You can access the conference call by dialing (866) 503-5561 (U.S. toll-free) or (253) 336-2965, using conference ID 5884198.

Where can I find the webcast for Evofem Biosciences' conference call?

The live webcast can be found on Evofem Biosciences' Investor page.

Will the Evofem Biosciences conference call be available for replay?

Yes, a telephone replay will be available approximately two hours after the call until August 7, 2020.